PHILADELPHIA (Dow Jones)--GlaxoSmithKline PLC (GSK) said the Food and Drug Administration approved a supplemental
Biologics License Application that expands the use of Bexxar for Non-Hodgkin's Lymphoma.
Bexxar was developed by Corixa Corp. (CRXA) and introduced under a collaboration agreement with GlaxoSmithKline. On Friday,
GlaxoSmithKline assumed full worldwide rights and responsibilities for manufacturing, clinical development and commercialization
of the drug.
In a press release Monday, GlaxoSmithKline said the expanded indication will make Bexxar an earlier option for patients with
relapsed low-grade, or follicular, non-Hodgkin's lymphoma.
The drug's original indication specified that patients have disease that was resistant to Rituximab and had relapsed following
chemotherapy.
Bexxar pairs the targeting ability of a monoclonal antibody the therapeutic potential of radiation. It is given in four visits over one to
two weeks, and is specifically dosed based on an individual's drug clearance rate, allowing the delivery of a predetermined amount
of radiation to each patient.
(MORE) Dow Jones Newswires
January 03, 2005 12:44 ET (17:44 GMT)
PHILADELPHIA (Dow Jones)--GlaxoSmithKline PLC (GSK) said the Food and Drug Administration approved a supplemental
Biologics License Application that expands the use of Bexxar for Non-Hodgkin's Lymphoma.
Bexxar was developed by Corixa Corp. (CRXA) and introduced under a collaboration agreement with GlaxoSmithKline. On Friday,
GlaxoSmithKline assumed full worldwide rights and responsibilities for manufacturing, clinical development and commercialization
of the drug.
In a press release Monday, GlaxoSmithKline said the expanded indication will make Bexxar an earlier option for patients with
relapsed low-grade, or follicular, non-Hodgkin's lymphoma.
The drug's original indication specified that patients have disease that was resistant to Rituximab and had relapsed following
chemotherapy.
Bexxar pairs the targeting ability of a monoclonal antibody the therapeutic potential of radiation. It is given in four visits over one to
two weeks, and is specifically dosed based on an individual's drug clearance rate, allowing the delivery of a predetermined amount
of radiation to each patient.
(MORE) Dow Jones Newswires
January 03, 2005 12:44 ET (17:44 GMT) |
